|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM354493345 |
| 003 |
DE-627 |
| 005 |
20231226062337.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.3928/23258160-20230217-02
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1181.xml
|
| 035 |
|
|
|a (DE-627)NLM354493345
|
| 035 |
|
|
|a (NLM)36944068
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wai, Karen M
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Evaluating the Effect of Hypoglycemic Agents on Diabetic Retinopathy Progression
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 23.03.2023
|
| 500 |
|
|
|a Date Revised 23.04.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a BACKGROUND AND OBJECTIVE: Newer hypoglycemics such as dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists have been increasingly used in diabetes. This study aimed to assess the relationship between usage of these hypoglycemic agents and effect on diabetic retinopathy (DR)
|
| 520 |
|
|
|a MATERIALS AND METHODS: Using the Vestrum Health Retina Database, patients with DR with 1 year follow-up after use of a hypoglycemic agent were included and stratified by agent, including no pharmacotherapy
|
| 520 |
|
|
|a RESULTS: Of 60,649 eyes, in 1 year after hypoglycemic agent usage, progression rates from severe nonproliferative diabetic retinopathy (NPDR) to proliferative diabetic retinopathy (PDR) were the following: DPP-4 (17%), SGLT-2 (12%), GLP-1 (21%), metformin (18%), and none (20%). Progression rates from moderate NPDR to severe NPDR or PDR were the following: DPP-4 (11%), SGLT-2 (10%), GLP-1 (11%), metformin (10%), none (13%). Progression rates from mild NPDR to moderate/severe NPDR or PDR were the following: DPP-4 (6%), SGLT-2 (9%), GLP-1 (9%), metformin (7%), and none (10%)
|
| 520 |
|
|
|a CONCLUSIONS: Within a large real-world database, patients prescribed GLP-1 agonists were found to have DR progression rates comparable to those of patients receiving no hypoglycemic agents. [Ophthalmic Surg Lasers Imaging Retina 2023; 54(3):158-165.]
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Hypoglycemic Agents
|2 NLM
|
| 650 |
|
7 |
|a Metformin
|2 NLM
|
| 650 |
|
7 |
|a 9100L32L2N
|2 NLM
|
| 650 |
|
7 |
|a Dipeptidyl-Peptidase IV Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Glucagon-Like Peptide 1
|2 NLM
|
| 650 |
|
7 |
|a 89750-14-1
|2 NLM
|
| 700 |
1 |
|
|a Saroj, Namrata
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Boucher, Nick
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Aggarwal, Nitika
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ho, Allen C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rahimy, Ehsan
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Ophthalmic surgery, lasers & imaging retina
|d 2013
|g 54(2023), 3 vom: 30. März, Seite 158-165
|w (DE-627)NLM224956647
|x 2325-8179
|7 nnns
|
| 773 |
1 |
8 |
|g volume:54
|g year:2023
|g number:3
|g day:30
|g month:03
|g pages:158-165
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3928/23258160-20230217-02
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_63
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_90
|
| 912 |
|
|
|a GBV_ILN_91
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_135
|
| 912 |
|
|
|a GBV_ILN_136
|
| 912 |
|
|
|a GBV_ILN_151
|
| 912 |
|
|
|a GBV_ILN_181
|
| 912 |
|
|
|a GBV_ILN_203
|
| 912 |
|
|
|a GBV_ILN_217
|
| 912 |
|
|
|a GBV_ILN_235
|
| 912 |
|
|
|a GBV_ILN_289
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_297
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_352
|
| 912 |
|
|
|a GBV_ILN_674
|
| 912 |
|
|
|a GBV_ILN_676
|
| 912 |
|
|
|a GBV_ILN_688
|
| 912 |
|
|
|a GBV_ILN_698
|
| 912 |
|
|
|a GBV_ILN_721
|
| 912 |
|
|
|a GBV_ILN_737
|
| 912 |
|
|
|a GBV_ILN_791
|
| 912 |
|
|
|a GBV_ILN_812
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 54
|j 2023
|e 3
|b 30
|c 03
|h 158-165
|